Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease-Reference-Cited by-同舟云学术

Hepatic steatosis and not type 2 diabetes, body mass index, or hepatic fibrosis associates with hyperglucagonemia in individuals with steatotic liver disease

Published:2024-10-01 Issue:4 Volume:327 Page:G558-G570
ISSN:0193-1857
Container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology
language:en
Short-container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology

Author:

Kjeldsen Sasha A. S.¹^ORCID,Werge Mikkel P.²,Grandt Josephine²^ORCID,Richter Michael M.¹³^ORCID,Thing Mira²,Hetland Liv E.²,Rashu Elias B.²,Jensen Anne-Sofie H.¹²^ORCID,Winther-Sørensen Marie¹^ORCID,Kellemann Jesper Sloth¹,Holst Jens J.⁴⁵,Junker Anders E.²,Serizawa Reza R.⁶,Vyberg Mogens⁶⁷,Gluud Lise Lotte²⁸,Wewer Albrechtsen Nicolai J.¹³^ORCID

Affiliation:

1. Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark

2. Gastro Unit, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark

3. Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

4. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

5. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

6. Department of Pathology, Copenhagen University Hospital, Amager and Hvidovre, Hvidovre, Denmark

7. Department of Clinical Medicine, Center for RNA Medicine, Aalborg University, Copenhagen, Denmark

8. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Abstract

Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) present with increased plasma levels of glucagon (hyperglucagonemia), irrespective of body mass index (BMI) and type 2 diabetes. Therefore, MASLD and the resultant hyperglucagonemia may act as a diabetogenic risk factor. Notably, hepatic steatosis was a significant contributor to the hyperglucagonemia in MASLD, potentially unveiling a pathway for the hyperglucagonemia in some patients with type 2 diabetes.

Funder

Novo Nordisk Fonden

Sundhed og Sygdom, Det Frie Forskningsråd

European Foundation for the Study of Diabetes

Publisher

American Physiological Society

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00147.2024

Reference60 articles.

1. Determinants of plasma levels of proglucagon and the metabolic impact of glucagon receptor signalling: a UK Biobank study

2. Kazda CM, Ding Y, Kelly RP, Garhyan P, Shi C, Lim CN, Fu H, Watson DE, Lewin AJ, Landschulz WH, Deeg MA, Moller DE, Hardy TA. Evaluation of efficacy and safetyof the glucagon receptor antagonist LY2409021 in patients with Type 2 diabetes: 12- andv24-week phase 2 studies. Diabetes Care 39:1241-1249, 2016. doi: 10.2337/dc15-1643.

3. Role of glucagon in disposal of an amino acid load

4. The Liver–α-Cell Axis in Health and in Disease

5. 100 years of glucagon and 100 more